Condition: Neovascular Age-Related Macular Degeneration (nAMD) · Sponsor: Ocular Therapeutix, Inc.
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
This description comes directly from the study's public registry record.
Clinical Project Manager · 781-357-4000 · clinicalaffairs@ocutx.com
Nichole Wilkes · 770-375-1020 · nwilkes@ocutx.com
Always discuss trial participation with your own doctor first.
| California Retina Consultants (CRC) | Bakersfield, California, United States | Recruiting |
| California Retina Consultants (CRC) | Santa Barbara, California, United States | Recruiting |
| Retina Group of New England | Waterford, Connecticut, United States | Recruiting |
| Retina Group of Florida - Fort Lauderdale | Fort Lauderdale, Florida, United States | Recruiting |
| Cumberland Valley Retina Associates | Hagerstown, Maryland, United States | Recruiting |
| Mid Atlantic Retina Specialists | Hagerstown, Maryland, United States | Recruiting |
| Palmetto Retina Center | West Columbia, South Carolina, United States | Recruiting |
| Austin Retina Associates | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07516132